Quantcast
Last updated on April 18, 2014 at 12:23 EDT

Latest Tacrolimus Stories

2009-08-03 21:06:00

CHICAGO, Aug. 3 /PRNewswire/ -- Eczema is a chronic skin disorder characterized by dry, itchy, scaly skin and rashes. It is commonly known as "the itch that rashes." (1) While the exact cause of eczema is not known, it appears to result from a complex interaction of factors including personal and family genetics, immune response and environmental factors. (2) Scratching the affected area can lead to more itch, redness, swelling, scaling, cracking, oozing clear fluid and, ultimately,...

2009-08-03 09:16:00

CHICAGO, Aug. 3 /PRNewswire/ -- Known medically as atopic dermatitis (AD), eczema is characterized by dry, itchy skin and rashes.(1) Scratching the affected area of skin may result in redness, swelling, scaling, cracking, weeping of clear fluid, and crusting of the skin.(2) Immuno-modulators called topical calcineurin (cal-SEE-nur-in) inhibitors (TCIs) can be effective treatments for patients with mild, moderate or severe eczema(3) who fail to respond adequately to first-line prescription...

2009-07-14 12:00:57

The U.S. Food and Drug Administration is ordering manufacturers of some immunosuppressant drugs used in kidney transplants to change their labeling. The FDA said the updated labels must reflect an increased risk of infections. The required label changes affect drugs used to help prevent rejection of transplanted organs. The drugs are Rapamune (sirolimus), Sandimmune (cyclosporine), and three generic drugs, Neoral (cyclosporine modified), Cellcept (mycophenolate mofetil) and Myfortic...

2009-05-31 16:15:00

The results of these studies will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009   COLUMBIA, Md., May 31 /PRNewswire/ -- The results of two large studies presented by researchers from the Starzl Transplant Institute at the University of Pittsburgh Medical Center demonstrated the long-term safety and efficacy of alemtuzumab induction and tacrolimus monotherapy.   (Logo: http://www.newscom.com/cgi-bin/prnh/20090424/NE99362LOGO )   Led...

2009-05-28 08:00:00

DEERFIELD, Ill., May 28 /PRNewswire/ -- The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf(R) (tacrolimus) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients. Prograf is a cornerstone therapy for preventing transplant rejection in liver, kidney and heart transplant recipients. The approval came on May 19, 2009 in response to a Supplemental New Drug Application (sNDA)...

2009-03-05 16:00:00

SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- Atopic dermatitis, the common, chronic, inflammatory skin disease marked by red, itchy rashes, has been increasing in prevalence over the past two decades and affects a disproportionate number of children. According to current estimates, approximately 15 percent to 20 percent of children in the United States and other industrialized countries around the world develop atopic dermatitis in the first few years of life. By comparison, only an...

2009-01-12 01:00:00

CAMBRIDGE, England, January 12 /PRNewswire/ -- Biotica Technology Limited, a privately-held biotechnology company, announces a significant Collaboration and License Agreement with GlaxoSmithKline to discover, develop and commercialise novel erythromycin-based macrolides in inflammatory diseases. In a three year research collaboration, Biotica will use its bioengineering technology to produce compounds that are not readily accessible via conventional medicinal chemistry approaches....

2008-10-30 03:00:27

Astellas Pharma has announced that its immunosuppressant Graceptor capsules 0.5mg, 1mg and 5mg are now available in Japan with the indication of 'suppression of organ rejection' and 'suppression of graft rejection and graft versus host disease in bone marrow transplantation'. Graceptor is a once-daily modified release formulation of Astellas's Prograf (tacrolimus, twice-daily formulation). Tacrolimus works as an immunosuppressant by inhibiting activation of T-cell. Graceptor maintains its...

2008-10-05 03:00:07

By Davies, Jill Hillman, Elizabeth Two local branch board members report on developing and running a study day on prescribing and the management of childhood eczema With the recently published National Institute for Health and Clinical Excellence (NICE) guidance on the management of atopic eczema in children1 and NMC Standards of proficiency for nurse and midwife prescribe(TM),2 this is an ideal time to update colleagues on prescribing for children with atopic eczema. As two health visitors...

2008-09-19 12:00:10

Maxygen and Astellas Pharma have announced a global agreement under which Astellas will receive worldwide rights to commercialize Maxy-4 lead candidates for all autoimmune diseases and transplant rejection. Under the agreement, the companies will co-develop Maxy-4 candidates for rheumatoid arthritis and other autoimmune diseases and Astellas will exclusively develop Maxy-4 candidates for transplant rejection. In addition, Maxygen has an option to co-promote any autoimmune therapeutic...